Population genetic structure of variable drug response

Geographic patterns of genetic variation, including variation at drug metabolizing enzyme (DME) loci and drug targets, indicate that geographic structuring of inter-individual variation in drug response may occur frequently. This raises two questions: how to represent human population genetic structure in the evaluation of drug safety and efficacy, and how to relate this structure to drug response. We address these by (i) inferring the genetic structure present in a heterogeneous sample and (ii) comparing the distribution of DME variants across the inferred genetic clusters of individuals. We find that commonly used ethnic labels are both insufficient and inaccurate representations of the inferred genetic clusters, and that drug-metabolizing profiles, defined by the distribution of DME variants, differ significantly among the clusters. We note, however, that the complexity of human demographic history means that there is no obvious natural clustering scheme, nor an obvious appropriate degree of resolution. Our comparison of drug-metabolizing profiles across the inferred clusters establishes a framework for assessing the appropriate level of resolution in relating genetic structure to drug response.

[1]  G. Kearns,et al.  Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. , 1999, Pharmacogenetics.

[2]  D. Labuda,et al.  Susceptibility to Childhood Acute Lymphoblastic Leukemia : Influence of CYP 1 A 1 , CYP 2 D 6 , GSTM 1 , and GSTT 1 Genetic Polymorphisms , 1999 .

[3]  D. Labuda,et al.  Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. , 1999, Blood.

[4]  J. Goldstein,et al.  Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. , 1996, Methods in enzymology.

[5]  G R Wilkinson,et al.  A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. , 1998, The Journal of pharmacology and experimental therapeutics.

[6]  F. Rousset,et al.  AN EXACT TEST FOR POPULATION DIFFERENTIATION , 1995, Evolution; international journal of organic evolution.

[7]  D. Grant,et al.  Molecular mechanism of slow acetylation of drugs and carcinogens in humans. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[9]  J. Brockmöller,et al.  Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. , 1999, British journal of clinical pharmacology.

[10]  P. Donnelly,et al.  Inference of population structure using multilocus genotype data. , 2000, Genetics.

[11]  D. Grant,et al.  NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. , 1998, Pharmacogenetics.

[12]  M Masellis,et al.  A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia , 2000, Molecular Psychiatry.

[13]  D. Goldstein,et al.  Consistent long-range linkage disequilibrium generated by admixture in a Bantu-Semitic hybrid population. , 2000, American journal of human genetics.

[14]  M. Ingelman-Sundberg,et al.  Nomenclature for human CYP2D6 alleles. , 1996, Pharmacogenetics.

[15]  Eric Minch,et al.  Genetic evidence for a higher female migration rate in humans , 1998, Nature Genetics.

[16]  M. Ingelman-Sundberg,et al.  Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. , 1999, Pharmacogenetics.

[17]  J. S. Miles,et al.  Identification of the primary gene defect at the cytochrome P450 CYP2D locus , 1990, Nature.

[18]  Chikayuki Naito,et al.  Ethnic Factors in the Acceptability of Foreign Clinical Data , 1998 .

[19]  U. Meyer,et al.  Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. , 1990, The Journal of biological chemistry.

[20]  U. Meyer,et al.  Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.